Available Clinical Trials at Pacific Cancer Care

Pacific Cancer Care is driven by a vision to be the leader for the treatment of cancer in the Monterey County. Our clinicians and investigators identify and conduct Phase I-IV treatment options that are new and innovative, and that will positively impact our patients. Below is a list of clinical trials currently available at Pacific Cancer Care.

For more information regarding clinical trial opportunities, please contact us at (831) 375-4105.

Solid Tumor and Hematologic Malignancies

Protocol Number: Patient-centered Outcomes Research Institute Study – Stanford – 63775

Protocol Title: Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults with Cancer

More Information available at: https://clinicaltrials.gov/ct2/show/NCT05297734

Eligibility criteria:

• Newly diagnosed cancer patients or recurrence of disease
• Must be 21 years or older
• Ability to understand and willing to provide informed consent
• Speak English or Spanish

Ineligibility criteria:

• Inability to consent to the study
• Plans to change their oncologist within 12 months
• Employed by the practice site
• Patients who anticipate moving away from the area within 12 months

Breast Cancer

Protocol Number: MK3475-B49

Protocol Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)

More information available at: https://clinicaltrials.gov/ct2/show/NCT04895358

Hematologic Malignancies

Protocol Number: MK-4280-003

Protocol Title: A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

More information available at: https://clinicaltrials.gov/ct2/show/NCT03598608

Ovarian Cancer

Protocol Number: MK-3475-B96

Protocol Title: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination with Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE B-96/ ENGOT-ov65)

More information available at: https://www.clinicaltrials.gov/ct2/show/NCT05116189